Laura Poliseno

Title: The Innovative Contributions of Laura Poliseno in Cancer Research

Introduction: Laura Poliseno is a distinguished inventor based in New York, NY, known for her groundbreaking work in cancer research. With a total of two patents to her name, she has made significant strides in the development of micro-RNA inhibitors, which hold promise in the treatment and prevention of various cancers.

Latest Patents: Laura’s latest patent focuses on "Micro-RNA inhibitors and their uses in disease." This invention details the treatment and prevention of cancer through the administration of agents that inhibit the activity of specific microRNAs. These microRNAs play crucial roles in modulating tumor suppressor genes such as PTEN, p53, and INPP4B. The inhibitors include oligonucleotides that are at least partially complementary to these miRNAs, with some embodiments showcasing chemically modified oligonucleotides like locked nucleic acids (LNAs).

Career Highlights: Laura Poliseno currently works at Beth Israel Deaconess Medical Center, Inc., where she continues to advance her research in oncogenetics and therapeutics. Her innovative contributions have propelled her into the forefront of cancer treatment strategies, further emphasizing her role as a vital asset in the medical research community.

Collaborations: In her career, Laura has collaborated with renowned colleagues, including Pier Paolo Pandolfi and Yvonne Tay. Together, they have contributed to an environment of innovation and discovery, pushing the boundaries of what is possible in cancer research.

Conclusion: Laura Poliseno exemplifies the type of inventor whose work can make a real difference in the treatment of diseases. With her expertise in micro-RNA inhibitors, she stands at the helm of innovative approaches to combating cancer, embodying the spirit of discovery and collaboration essential to modern scientific progress. Her patents represent not just technical advancements but also hope for future treatments and therapies in the medical field.